【礼来支持的Scribe Therapeutics美国IPO，首日飙升超44%】专注于心脏病基因疗法的临床阶段开发商Scribe Therapeutics Inc.，通过扩大规模的IPO筹集1.287亿美元后，周五股价收盘飙升44.33%。文件显示，赛诺菲的关联公司已同意以IPO价格购买约750万美元的股份，作为同步私募配售的一部分。Scribe的现有支持者之一礼来公司表示有兴趣在IPO中购买更多股份，以便在发行和配售后持有Scribe高达11%的股份。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.